Recent years have witnessed remarkable progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as promising candidates, showing exceptional results in clinical trials. Retatrutide, a dual glucagon-like peptide-1 (GLP-1) and glucose-depe